Condition
Esophageal Squamous Cell Carcinoma
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 42 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
42 shownEvaluation of Skin Tests in Biotherapy AllergiesNCT06971848 · 2026-06-17
RECRUITINGA Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors TypesNCT07503808 · 2026-02-24
RECRUITINGFirst-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid TumorsNCT07284186 · 2025-12-01
RECRUITINGA Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell CarcinomasNCT07217171 · 2025-11-13
RECRUITINGA Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway AlterationsNCT07109726 · 2025-09-23
RECRUITINGA Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid TumorsNCT07090499 · 2025-08-20
RECRUITINGA Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid TumorsNCT06747585 · 2024-12-16
RECRUITINGStudy to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400NCT06084481 · 2023-11-09
RECRUITINGSafety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain MetastasisNCT06047379 · 2023-11-01
RECRUITINGA Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)NCT05319730 · 2023-05-16
RECRUITINGA Study of PF-08046054/SGN-PDL1V in Advanced Solid TumorsNCT05208762 · 2022-10-25
RECRUITINGRAPA-201 Therapy of Solid TumorsNCT05144698 · 2021-08-01
RECRUITINGA Study of Sigvotatug Vedotin in Advanced Solid TumorsNCT04389632 · 2020-06-08
RECRUITINGA Multicenter Cancer Biospecimen Collection StudyNCT04510129 · 2020-02-05
RECRUITINGA Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.NCT07623642 · 2026-06-02
NOT_YET_RECRUITINGA Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 MutationNCT06560645 · 2024-11-04
TERMINATEDA Study of SGN-B6A in Chinese Participants With Advanced Solid TumorsNCT06549816 · 2024-08-21
COMPLETEDPPIO-007 Correlation Analysis of Type II Diabetes Mellitus on Short-term and Long-term Outcomes of Patients With Esophageal Squamous Cell Cancer Undergoing Minimally Invasive EsophagectomyNCT06333665 · 2024-02-20
COMPLETEDSafety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid TumorsNCT05799274 · 2023-11-09
ACTIVE_NOT_RECRUITINGStudy of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer TypesNCT06034860 · 2023-11-01
TERMINATEDCadonilimab/Anlotinib in Locally Advanced or Relapsed/Metastatic ESCC Patients After Failure of PD-1 Combined With Platinum-containing ChemotherapyNCT05990231 · 2023-09-01
UNKNOWNA Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With Advanced Solid TumorsNCT05462873 · 2023-04-04
TERMINATEDPembrolizumab Plus Chemo in Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma (Eastern Cooperative Thoracic Oncology Projects 2004, ECTOP-2004)NCT05281003 · 2023-02-20
UNKNOWNAnti-PD-1 Immunotherapy Combined With SBRT for Patients With Oligometastatic ESCCNCT05626569 · 2022-12-10
UNKNOWNPembrolizumab and Photodynamic Therapy in Previously Treated Metastatic Esophageal Squamous Cell CarcinomaNCT05386056 · 2022-12-01
NOT_YET_RECRUITINGA Phase II Study of CRT Combined With QL1706 in ESCC PatientsNCT05490719 · 2022-08-01
UNKNOWNStudy Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IONCT05078047 · 2022-03-08
ACTIVE_NOT_RECRUITINGPhase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in CombinationNCT04868877 · 2021-04-28
ACTIVE_NOT_RECRUITINGJAB-3068 Activity in Adult Patients With Advanced Solid TumorsNCT04721223 · 2021-04-26
COMPLETEDExploration of Immunodynamic Monitoring in the Population Evaluation of Neoadjuvant Chemotherapy Immunotherapy in Patients With Solid Tumors of the Chest.NCT05044728 · 2021-04-01
UNKNOWNSafety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid TumorsNCT04272034 · 2021-03-26
TERMINATEDSafety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid TumorsNCT04242199 · 2020-09-04
COMPLETEDA Study of JAB-3312 in Adult Patients With Advanced Solid Tumors in ChinaNCT04121286 · 2020-07-14
COMPLETEDA Phase 1b Trial of ATRC-101 in Adults With Advanced Solid MalignanciesNCT04244552 · 2020-02-11
TERMINATEDDose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid TumorsNCT04140500 · 2019-11-11
ACTIVE_NOT_RECRUITINGA Study of Ladiratuzumab Vedotin in Advanced Solid TumorsNCT04032704 · 2019-10-09
TERMINATEDA First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid TumorsNCT04045496 · 2019-09-26
COMPLETEDGB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic AdenocarcinomaNCT04060342 · 2019-08-13
TERMINATEDHIV and Other Risk Factors for Esophageal Squamous Cell Carcinoma in MalawiNCT03160209 · 2017-07-26
COMPLETEDDurvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid TumorsNCT02658214 · 2016-04-28
COMPLETEDOral Rigosertib for Squamous Cell CarcinomaNCT01807546 · 2013-03-01
COMPLETEDA Phase I Study of LJM716 in Squamous Cell Carcinoma of Head and Neck, or HER2+ Breast Cancer or Gastric CancerNCT01598077 · 2012-07-01
COMPLETEDCommon interventions
pembrolizumabDRUG7PaclitaxelDRUG3BevacizumabDRUG2CarboplatinDRUG2cisplatinDRUG2JAB-3312DRUG2NivolumabDRUG2PembrolizumabBIOLOGICAL2sigvotatug vedotinDRUG2ABBV-400DRUG1Acetaminophen (or equivalent)DRUG1ALE.P02DRUG1Anti-PD-1 antibody combined with Paclitaxel and carboplatin.DRUG1anti-PD-1 monoclonal antibodiesDRUG1AntihistamineDRUG1ATRC-101BIOLOGICAL1Cadonilimab combined AnlotinibDRUG1CarboplatinCOMBINATION_PRODUCT1carboplatin + etoposideDRUG1ChemotherapyDRUG1Chemotherapy Prior to RAPA-201 TherapyDRUG1CisplatinCOMBINATION_PRODUCT1cisplatin + 5-fluorouracil (5FU)DRUG1Dexamethasone (or equivalent)DRUG1Drug skin tests (investigating hypersensitivity to a biotherapy)OTHER1
Leading sponsors
Seagen, a wholly owned subsidiary of Pfizer
3
Incyte Corporation
2
Jacobio Pharmaceuticals Co., Ltd.
2
Novartis Pharmaceuticals
2
AbbVie
1
Alentis Therapeutics AG
1
Allist Pharmaceuticals, Inc.
1
AstraZeneca
1
Atreca, Inc.
1
Cofactor Genomics, Inc.
1
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
1
EvolveImmune United, Inc
1
Fudan University
1
GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.
1
GV20 Therapeutics
1
Trial status mix
RECRUITING14
COMPLETED10
TERMINATED7
UNKNOWN5
ACTIVE_NOT_RECRUITING4
NOT_YET_RECRUITING2
Phase mix
PHASE128
PHASE217
NA1
PHASE31
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.